ES2155819T3 - Inmunoglobulinas hibridas. - Google Patents

Inmunoglobulinas hibridas.

Info

Publication number
ES2155819T3
ES2155819T3 ES91901202T ES91901202T ES2155819T3 ES 2155819 T3 ES2155819 T3 ES 2155819T3 ES 91901202 T ES91901202 T ES 91901202T ES 91901202 T ES91901202 T ES 91901202T ES 2155819 T3 ES2155819 T3 ES 2155819T3
Authority
ES
Spain
Prior art keywords
hybrid immunoglobulins
useful
methods
peptides
immunoglobulins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91901202T
Other languages
English (en)
Other versions
ES2155819T5 (es
Inventor
Daniel J Capon
Laurence A Lasky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23749509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2155819(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2155819T3 publication Critical patent/ES2155819T3/es
Publication of ES2155819T5 publication Critical patent/ES2155819T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)

Abstract

Procedimiento de fabricación de un dímero de cadena pesada de inmunoglobulina, en el cual una secuencia aminoacídica de una pareja de unión al ligando que es una cadena única y es un receptor, una proteína transportadora, una hormona, un factor de crecimiento o una enzima y no es un receptor de localización de linfocitos, no es un miembro de la superfamilia de genes de inmunoglobulinas ni una proteína homóloga a éstos, ni tampoco un polipéptido de subunidades múltiples codificadas por genes discretos, se sustituye por las regiones variables de las cadenas pesadas de inmunoglobulina, en donde dichas cadenas pesadas de inmunoglobulina retienen al menos bisagra y los dominios CH2 y CH3 de la región constante de cadena pesada.
ES91901202T 1989-11-22 1990-11-21 Inmunoglobulinas hibridas. Expired - Lifetime ES2155819T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/440,625 US5116964A (en) 1989-02-23 1989-11-22 Hybrid immunoglobulins
US440625 1989-11-22

Publications (2)

Publication Number Publication Date
ES2155819T3 true ES2155819T3 (es) 2001-06-01
ES2155819T5 ES2155819T5 (es) 2007-09-16

Family

ID=23749509

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99123412T Expired - Lifetime ES2308826T3 (es) 1989-11-22 1990-11-21 Inmunoglobulinas hibridas para su uso en metodos terapeuticos.
ES91901202T Expired - Lifetime ES2155819T5 (es) 1989-11-22 1990-11-21 Inmunoglobulinas hibridas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99123412T Expired - Lifetime ES2308826T3 (es) 1989-11-22 1990-11-21 Inmunoglobulinas hibridas para su uso en metodos terapeuticos.

Country Status (13)

Country Link
US (1) US5116964A (es)
EP (3) EP1970386A2 (es)
JP (2) JPH05503009A (es)
AT (2) ATE396735T1 (es)
CA (1) CA2072642C (es)
DE (3) DE122008000063I2 (es)
DK (2) DK0526452T4 (es)
ES (2) ES2308826T3 (es)
GR (1) GR3035856T3 (es)
HK (2) HK1013298A1 (es)
LU (1) LU91498I2 (es)
NL (1) NL300372I1 (es)
WO (1) WO1991008298A2 (es)

Families Citing this family (612)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
ES2238070T3 (es) * 1989-04-21 2005-08-16 Amgen Inc. Receptor del tnf, proteina ligante del tnf y adn codante para estos.
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6267964B1 (en) * 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
DE4037837A1 (de) * 1990-11-28 1992-06-04 Behringwerke Ag Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung
US7070991B2 (en) * 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
EP1340769B1 (en) 1991-02-08 2005-02-09 Progenics Pharmaceuticals, Inc. CD4-gamma2 and CD4-IgG2 chimeras
WO1992016622A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Cd2-binding domain of lymphocyte function associated antigen 3
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5318890A (en) * 1991-05-06 1994-06-07 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US6399368B1 (en) 1992-01-17 2002-06-04 Board Of Regents, The University Of Texas System Secretion of T cell receptor fragments from recombinant Escherichia coli cells
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
AU4116793A (en) * 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO1994006456A1 (en) * 1992-09-16 1994-03-31 Genentech, Inc. Protection against liver damage by hgf
WO1994006469A1 (en) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Hiv fusion polypeptide
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5474766A (en) * 1992-12-18 1995-12-12 Washington University Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
JPH08506017A (ja) * 1993-01-25 1996-07-02 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ドメインの交換によるキメラｌ‐およびｐ‐セレクチン、ならびにそれらの使用
US7534867B1 (en) 1993-05-19 2009-05-19 Schering Corporation Purified mammalian Flt3 ligands; agonists; antagonists
US6723705B1 (en) 1993-08-19 2004-04-20 Gentics Institute, Inc. Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US20050129670A1 (en) * 1993-07-26 2005-06-16 Genetics Institute, Llc. Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
SE9302855D0 (sv) * 1993-09-06 1993-09-06 Martin Lindberg Method and means for producing plasmaproteinase inhibitor binding proteins
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
CA2182498A1 (en) * 1994-02-01 1995-08-10 William J. Larochelle Fusion proteins that include antibody and nonantibody portions
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
AU709711B2 (en) 1994-03-08 1999-09-02 Dana-Farber Cancer Institute Methods for modulating T cell unresponsiveness
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
IL113484A0 (en) * 1994-04-28 1995-07-31 Immunex Corp Viral proteins pharmaceutical compositions containing them their preparation and use
MX9605365A (es) 1994-05-06 1997-12-31 Roussy Inst Gustave Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo.
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6410008B1 (en) * 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
EP1621206A1 (en) * 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US6808709B1 (en) * 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US20030069196A1 (en) * 1995-03-03 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US6455685B1 (en) 1995-03-03 2002-09-24 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
AU696775B2 (en) * 1995-03-23 1998-09-17 Kirin-Amgen, Inc. IL-17 receptor
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
US20060193862A1 (en) * 1995-03-30 2006-08-31 Genentech, Inc. Vascular endothelial cell growth factor antagonists
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US20030026779A1 (en) * 1999-10-15 2003-02-06 Liming Yu Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
DE69739677D1 (de) 1996-01-08 2010-01-07 Genentech Inc OB Rezeptor-Variante und Liganden
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5917026A (en) * 1996-02-05 1999-06-29 Loewenadler; Bjoern Fusion proteins of immunopotentiating activity
JP4344404B2 (ja) 1996-02-09 2009-10-14 アムジェン インコーポレイテッド インターロイキン―１インヒビターおよび制御放出ポリマーを含む組成物
BR9707589A (pt) 1996-02-20 2000-01-04 Applied Research Systems Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular.
US6194177B1 (en) * 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein
GB9604518D0 (en) * 1996-03-02 1996-05-01 Smithkline Beecham Plc Novel compounds
AU729406B2 (en) * 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6140305A (en) * 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US7063965B2 (en) * 1996-04-05 2006-06-20 Regeneron Pharmaceuticals, Inc. Nucleic acid encoding TIE-2 ligand
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US6117977A (en) * 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
US6451308B1 (en) * 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
CA2252557A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15
ATE299936T1 (de) * 1996-05-02 2005-08-15 Mochida Pharm Co Ltd Fas antigen-derivate
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
AU727606B2 (en) * 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
NZ333325A (en) * 1996-07-12 2000-06-23 Genentech Inc Recombinant chimeric heteromultimer adhesins comprising extracellular domains of ErbB receptors
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
AU736876B2 (en) 1996-12-06 2001-08-02 Amgen, Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
WO1998033914A1 (en) * 1997-01-31 1998-08-06 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6268411B1 (en) * 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7435793B2 (en) * 1998-05-15 2008-10-14 Genentech, Inc. Peptides that induce chondrocyte redifferentiation
PT975755E (pt) 1997-04-16 2007-06-26 Millennium Pharm Inc Proteínas crsp (proteínas segregadas ricas em cisteínas), moléculas de ácido nucleico que as codificam e suas utilizações
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
CA2288351A1 (en) * 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP1757614B1 (en) 1997-06-13 2010-03-31 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
US6956108B2 (en) * 1997-06-16 2005-10-18 Genentech, Inc. PRO1184 antibodies
US20040191256A1 (en) * 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US20030166106A1 (en) * 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
WO1999020758A1 (en) * 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US20040136986A1 (en) * 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
AU763719B2 (en) 1997-12-08 2003-07-31 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6207413B1 (en) * 1998-01-22 2001-03-27 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding novel orphan cytokine receptors
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7723488B2 (en) * 1998-03-27 2010-05-25 Genentech, Inc. Monoclonal antibodies to secreted and transmembrane polypeptides
US7371836B2 (en) * 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
PL343462A1 (en) * 1998-04-15 2001-08-13 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
ATE365800T1 (de) * 1998-05-15 2007-07-15 Genentech Inc Therapeutische verwendungen von il-17 homologe polypeptide
US20030032061A1 (en) * 1998-05-15 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2395693T3 (es) 1998-06-12 2013-02-14 Genentech, Inc. Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la fabricación de los mismos
US6548653B1 (en) * 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US20070003545A9 (en) * 1999-06-02 2007-01-04 Eaton Dan L Interleukin-8 homologous polypeptides and therapeutic uses thereof
US20030065154A1 (en) * 2000-03-30 2003-04-03 Genentech, Inc. Interleukin-8 homologous polypeptides and therapeutic uses thereof
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
US20020099197A1 (en) * 1998-07-21 2002-07-25 Rory A.J. Curtis Novel potassium channel molecules and uses therefor
CN100473417C (zh) * 1998-08-31 2009-04-01 安斯泰来美国有限责任公司 Cd2-结合剂调节记忆效应t-细胞的制药用途和组合物
EP2599503B1 (en) * 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
PT1121382E (pt) * 1998-10-16 2006-10-31 Biogen Idec Inc Proteinas de fusao do interferao beta e as respectivas utilizacoes
PL219605B1 (pl) 1998-10-23 2015-06-30 Kirin Amgen Inc Dimeryczne mimetyki peptydów trombopoetynowych wiążące się z receptorem MP1 i wykazujące aktywność trombopoetyczną
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000027885A1 (fr) * 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique
JP2002529090A (ja) * 1998-11-10 2002-09-10 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ケモカインβ−７
US7294482B2 (en) * 1998-11-19 2007-11-13 Millennium Pharmaceuticals, Inc. EGF-like nucleic acids
US7238790B2 (en) * 1999-01-12 2007-07-03 Genentech, Inc. PRO1313 polypeptides
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
AU764382B2 (en) 1999-03-19 2003-08-14 Genentech Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
US7011833B1 (en) * 1999-05-06 2006-03-14 Genetics Institute, Inc. Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
US20050079577A1 (en) * 1999-05-14 2005-04-14 Ashkenazi Avi J. Secreted and transmembrane polypeptides and nucleic acids encoding the same
BR0010725A (pt) * 1999-05-19 2002-02-19 Lexigen Pharm Corp Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
IL146842A0 (en) * 1999-06-01 2002-07-25 Biogen Inc Polymer conjugates of hedgehog proteins and uses
AU5309600A (en) * 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
CA2373721C (en) 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
WO2001001749A2 (en) * 1999-07-02 2001-01-11 Genentech, Inc. FVIIa ANTAGONISTS
CA2378796A1 (en) * 1999-07-12 2001-01-18 Merck Patent Gesellschaft Mit Beschraenkter Haftung Seripancrin
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU6607100A (en) * 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
EP1203014B1 (en) * 1999-08-06 2004-10-13 Genentech, Inc. Peptide antagonists of factor viia
HUP0202442A3 (en) * 1999-08-09 2005-01-28 Lexigen Pharmaceuticals Corp L Multiple cytokine-antibody complexes
JP4896327B2 (ja) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｐｄ−１、ｂ７−４の受容体、およびその使用
US20020173627A1 (en) * 1999-09-16 2002-11-21 Samuel Davis TIE-2 ligands, methods of making and uses thereof
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
JP2003513660A (ja) * 1999-11-05 2003-04-15 バイオジェン インコーポレイテッド ヘッジホッグ融合タンパク質及び利用
WO2001036489A2 (en) 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7122632B2 (en) * 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
US7307153B2 (en) * 1999-12-23 2007-12-11 Genentech, Inc. Antibodies that bind PRO9912
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
US20030153015A1 (en) * 2000-01-20 2003-08-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US20060073547A1 (en) * 2000-03-01 2006-04-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6984519B2 (en) 2000-03-01 2006-01-10 Genetech, Inc. Nucleic acids encoding peptides that induce chondrocyte redifferentiation
US20060002943A1 (en) * 2000-03-02 2006-01-05 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US20030207293A1 (en) * 2000-04-10 2003-11-06 Klaus Ducker Cryptic-like secreted protein
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
ES2484966T3 (es) * 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20060015969A1 (en) * 2000-04-28 2006-01-19 Planet Biotechnology, Inc. Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases
JP5008811B2 (ja) * 2000-04-28 2012-08-22 プラネット・バイオテクノロジー・インコーポレイテッド ライノウイルス感染を防止するための免疫接着物
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
US20020102232A1 (en) * 2000-05-11 2002-08-01 Chang Tse W. Compositions and methods for induction of active autoimmunity
CA2408691A1 (en) * 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
EP1714661A3 (en) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
US20040034193A1 (en) * 2001-06-13 2004-02-19 Samy Ashkar Biosynthetic oncolytic molecules and uses therefor
AU2001273032A1 (en) * 2000-06-26 2002-01-08 Zymogenetics Inc. Cytokine receptor zcytor17
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
AU2001273096B8 (en) 2000-06-28 2005-10-13 Dana-Farber Cancer Institute, Inc. PD-L2 molecules: novel PD-1 ligands and uses therefor
DK1294401T3 (da) * 2000-06-29 2007-10-08 Merck Patent Gmbh Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP2177616B1 (en) * 2000-08-08 2012-02-29 ZymoGenetics, Inc. Soluble zcytor 11 cytokine receptors
US20030215916A1 (en) * 2000-08-18 2003-11-20 Feder John N. Novel imidazoline receptor homologs
AU2001287000A1 (en) 2000-09-01 2002-03-13 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
RU2280255C2 (ru) * 2000-09-14 2006-07-20 Бет Изрейэл Диконисс Медикал Сентер, Инк. Модуляция il-2- и il-15-опосредованных т-клеточных ответов
NZ524329A (en) 2000-09-26 2008-04-30 Genentech Inc IgE receptor antagonists that compete with IgE134 for binding to the receptor
US7241590B2 (en) * 2000-09-29 2007-07-10 Bristol-Myers Squibb Company Identification and cloning of a full-length human Clnk-related gene, MIST (mast cell immunoreceptor signal transducer)
US20030211549A1 (en) * 2000-10-06 2003-11-13 Murphy Andrew J. Functional proteins and therapeutic and diagnostic methods for use thereof
CA2425396A1 (en) * 2000-11-07 2002-06-13 Board Of Regents, The University Of Texas System Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
US20030124142A1 (en) * 2000-12-04 2003-07-03 Fraser John David Immunomodulatory constructs and their uses
PT1642910E (pt) * 2000-12-05 2012-03-22 Alexion Pharma Inc Anticorpos concebidos de modo racional
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
AU2002250076A1 (en) * 2001-02-16 2002-09-04 Bristol-Myers Squibb Company Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, hgra4, and splice variant thereof
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
EP1395605B8 (en) 2001-03-09 2014-12-17 Iterative Therapeutics, Inc. Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors
US8163289B2 (en) 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
MXPA03008959A (es) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, un receptor para b7-4 y sus usos.
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
ITRE20010042A1 (it) * 2001-04-24 2002-10-24 Corghi Spa Dispositivo sollevatore per macchine smontagomme
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
DK1383785T3 (da) 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
CN100448891C (zh) 2001-05-11 2009-01-07 安姆根有限公司 与tall-1结合的肽和相关分子
WO2002102320A2 (en) * 2001-06-15 2002-12-27 Tanox, Inc. Fce fusion proteins for treatment of allergy and asthma
WO2004081026A2 (en) * 2003-06-30 2004-09-23 Domantis Limited Polypeptides
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2454618C (en) * 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
WO2003015697A2 (en) * 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
HU230373B1 (hu) 2001-08-29 2016-03-29 Genentech Inc Mitogén aktivitású Bv8-nukleinsavak és polipeptidek
JP2005508623A (ja) * 2001-08-30 2005-04-07 バイオレクシス ファーマシューティカル コーポレイション 改変されたトランスフェリン融合タンパク質
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
AU2002332041A1 (en) * 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
DE60224822T2 (de) * 2001-10-19 2009-01-22 Zymogenetics, Inc., Seattle Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
US7368114B2 (en) * 2001-10-25 2008-05-06 The United States Of America As Represented By The Department Of Health And Human Services Fusion protein including of CD4
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
MXPA04005266A (es) 2001-12-04 2004-10-11 Merck Patent Gmbh Inmunocitocinas con selectividad modulada.
US7858297B2 (en) * 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
CA2471777A1 (en) * 2001-12-18 2003-06-26 Endocube Sas Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
RS55578B1 (sr) * 2002-01-18 2017-06-30 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
PL211833B1 (pl) 2002-01-18 2012-06-29 Zymogenetics Inc Wyizolowany polipeptyd, białko fuzyjne, wyizolowana cząsteczka polinukleotydu, wektor ekspresji, hodowana komórka, sposób wytwarzania polipeptydu, sposób wytwarzania przeciwciała, przeciwciało, przeciwciało lub fragment przeciwciała, zastosowanie przeciwciała, sposób wykrywania obecności polipeptydu, sposób inhibicji proliferacji lub różnicowania komórek krwiotwórczych, zastosowanie polipeptydu, sposób rozprzestrzeniania komórek krwiotwórczych, sposób wykrywania obecności RNA, sposób zabijania komórek nowotworowych in vitro lub in vivo, zastosowanie polipeptydu, zastosowanie antagonisty polipeptydu i sposób wykrywania zapalenia u pacjenta
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
US20030211470A1 (en) * 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
CN1665839A (zh) * 2002-04-10 2005-09-07 应用研究系统Ars股份公司 Mcp蛋白质的新型拮抗剂
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
KR100864901B1 (ko) 2002-05-29 2008-10-22 야마사 쇼유 가부시키가이샤 신규 폴리포스페이트:에이엠피 포스포트랜스퍼라제
WO2003101485A1 (en) * 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
NZ519371A (en) * 2002-06-04 2004-11-26 Auckland Uniservices Ltd Immunomodulatory constructs and their uses
US7531178B2 (en) * 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (en) * 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
US20090130021A1 (en) * 2002-06-07 2009-05-21 Gotz Munch Methods, products and uses involving platelets and/or the vasculature
US20070071744A1 (en) * 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
AU2003280130B2 (en) 2002-06-28 2009-06-11 Centocor, Inc. Mammalian CH1 deleted mimetibodies, compositions, methods and uses
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
CA2493081C (en) * 2002-07-12 2013-04-23 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
JP4776228B2 (ja) * 2002-07-15 2011-09-21 ワイス・エルエルシー Ｔヘルパー（ｔｈ）細胞の発生および機能を調節するための方法および組成物
US20040110681A1 (en) * 2002-08-08 2004-06-10 Xiao-Min Fan Method to identify targeting molecules
MXPA05002219A (es) 2002-08-28 2005-07-05 Immunex Corp Composiciones y metodos para tratar una enfermedad cardiovascular.
DE10251463A1 (de) * 2002-11-05 2004-05-19 BSH Bosch und Siemens Hausgeräte GmbH Elektrisch angetriebene Pumpe
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
AU2003298187B2 (en) * 2002-12-17 2010-09-16 Merck Patent Gmbh Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
AU2004204817C1 (en) * 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
BRPI0407108A (pt) * 2003-02-06 2006-01-24 Novozymes As Método para produzir uma imunoglobulina funcional humana
US20050096264A1 (en) * 2003-02-25 2005-05-05 Macdonald Lynn Methods for treating obesity and related conditions with glycoprotein hormone beta family hormones
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
WO2004085476A2 (en) * 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
ATE438662T1 (de) 2003-03-26 2009-08-15 Apogenix Gmbh Verbesserte fc-fusionsproteine
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP3552627A1 (en) * 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
CA2522690A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
EP1622939B1 (en) * 2003-05-13 2012-03-14 Merck Serono SA Active variants of the il-18 binding protein and medical uses thereof
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
EP1631266B1 (en) 2003-05-13 2011-03-16 DePuy Spine, Inc. A method of treating degenerative disc disease
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7435808B2 (en) * 2003-06-25 2008-10-14 Bristol-Myers Squibb Company Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
PL2520654T3 (pl) 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US20070274988A1 (en) * 2003-10-10 2007-11-29 Five Prime Therapeautics, Inc. Kiaa0779, Splice Variants Thereof, and Methods of Their Use
US20050239700A1 (en) * 2003-10-14 2005-10-27 Biogen Idec Inc. Treatment of cancer using antibodies to LRRC15
US8129506B2 (en) * 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
KR100725315B1 (ko) * 2003-11-13 2007-06-07 한미약품 주식회사 면역글로불린 단편을 이용한 단백질 결합체 및 그의제조방법
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
PL1699822T3 (pl) * 2003-12-30 2008-08-29 Merck Patent Gmbh Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie
CA2551916C (en) * 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1706428B1 (en) * 2004-01-22 2009-09-23 MERCK PATENT GmbH Anti-cancer antibodies with reduced complement fixation
BRPI0507404A (pt) * 2004-02-06 2007-06-26 Astellas Us Llc método de tratamento de um indivìduo que tem psorìase e kit
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
SG151315A1 (en) * 2004-03-31 2009-04-30 Centocor Inc Human glp-1 mimetibodies, compositions, methods and uses
EP1747291A2 (en) * 2004-05-04 2007-01-31 Genaissance Pharmaceuticals, Inc. Haplotype markers and methods of using the same to determine response to treatment
US7662921B2 (en) * 2004-05-07 2010-02-16 Astellas Us Llc Methods of treating viral disorders
US20060063208A1 (en) * 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
ES2347340T3 (es) 2004-09-13 2010-10-28 Genzyme Corporation Construcciones multimericas.
ES2629397T3 (es) 2004-09-24 2017-08-09 Amgen Inc. Moléculas de Fc modificadas
PL1802334T3 (pl) 2004-10-21 2013-01-31 Genentech Inc Sposób leczenia wewnątrzgałkowych chorób neowaskularnych
DK1812476T3 (da) 2004-10-22 2010-10-25 Zymogenetics Inc Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation
US20090311259A1 (en) * 2004-11-17 2009-12-17 Victoria Smith Compositions and Methods for Treatment of Tumor of Hematopoietic Origin
ES2342964T3 (es) * 2004-12-09 2010-07-20 Merck Patent Gmbh Variantes de la interleucina-7 con inmunogenicidad reducida.
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
EA200701448A1 (ru) 2005-01-05 2008-02-28 Байоджен Айдек Эмэй Инк. Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
ATE481978T1 (de) 2005-01-25 2010-10-15 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
US20090155267A1 (en) * 2005-02-09 2009-06-18 Apollo Life Sciences Limited Molecule and chimeric molecules thereof
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
AU2006259298B2 (en) 2005-06-17 2012-06-14 Wyeth Llc Methods of purifying Fc region containing proteins
LT2452694T (lt) 2005-06-30 2019-02-25 Janssen Biotech, Inc. Anti-il-23 antikūnai, kompozicijos, būdai ir panaudojimai
JP2009502123A (ja) 2005-07-08 2009-01-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５抗体およびその使用
EP1926747A1 (en) * 2005-08-12 2008-06-04 Schering Corporation Mcp1 fusions
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2616479A1 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
BRPI0617330A2 (pt) * 2005-10-13 2011-07-19 Virexx Medical Corp antìgeno quimérico contendo polipeptìdeo do vìrus da hepatite c e fragmento fc para despertar uma resposta imunológica
TW200722436A (en) * 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
CA2628928A1 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
EA015526B1 (ru) * 2005-11-14 2011-08-30 Ринат Ньюросайенс Корп. Антагонистические антитела против пептида, связанного с геном кальцитонина, и способы их применения
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
JP2009521503A (ja) * 2005-12-22 2009-06-04 ディー・エイチ・ワイ・アンド・カンパニー・リミテッド インターロイキン−２２結合タンパク質に対する抗体と、代謝性疾患の処置のためのその使用
DK3219328T3 (da) 2005-12-29 2020-07-13 Janssen Biotech Inc Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
DK1966245T3 (da) 2005-12-30 2011-07-18 Merck Patent Gmbh Anti-CD19-Antistoffer med reduceret immunogenicitet
BRPI0620648B1 (pt) * 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
JP2009526756A (ja) 2006-01-10 2009-07-23 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP1991577A2 (en) 2006-01-31 2008-11-19 Parkinson, John F. Modulation of mdl-1 activity for treatment of inflammatory disease
GB0604187D0 (en) * 2006-03-02 2006-04-12 Fusion Antibodies Ltd Peptide and uses thereof
US20090306349A1 (en) * 2006-03-31 2009-12-10 Rampak Corp Binding partners with immunoglobulin domains modified to have extended half-life
EA020805B1 (ru) 2006-05-24 2015-01-30 Мерк Сероно С.А. Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза
NZ574093A (en) * 2006-06-12 2011-03-31 Symphogen As Pan-cell surface receptor- specific therapeutics
AU2007261247A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-C35 antibodies for treating cancer
US20100021379A1 (en) * 2006-06-29 2010-01-28 The Regents Of The University Of California Chemical Antibodies for Immunotherapy and Imaging
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US20080014285A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
EP2068889B1 (en) 2006-08-10 2019-10-23 Roy C. Levitt Anakinra for use in the treatment of bronchiolitis obliterans syndrome
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
AU2007353396C1 (en) 2006-11-02 2013-06-27 Biomolecular Holdings Llc Hybrid immunoglobulins with moving parts
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
CN101622275B (zh) 2007-01-05 2013-11-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
DK2740744T3 (da) 2007-01-09 2018-04-23 Biogen Ma Inc Sp35-antistoffer og anvendelser deraf
CA2678493A1 (en) 2007-02-23 2008-08-28 The Trustees Of Columbia University In The City Of New York Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease
AU2008227024A1 (en) * 2007-03-07 2008-09-18 Glycofi, Inc. Production of glycoproteins with modified fucosylation
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
US7906149B2 (en) * 2007-05-25 2011-03-15 Boval Company, L.P. Method for treating allergic dermatitis
ES2456963T3 (es) * 2007-06-04 2014-04-24 Rappaport Family Institute For Research In The Medical Sciences Agentes para el tratamiento de enfermedades inflamatorias y métodos para usar los mismos
MX2009012968A (es) * 2007-06-06 2010-04-01 Domantis Ltd Polipeptidos, dominios variables de anticuerpo y antagonistas.
US8067548B2 (en) 2007-07-26 2011-11-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
GB0717337D0 (en) * 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
WO2009046541A1 (en) 2007-10-11 2009-04-16 University Health Network MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR
US20100278801A1 (en) * 2007-10-16 2010-11-04 Shepard H Michael Compositions comprising optimized her1 and her3 multimers and methods of use thereof
CA2703263C (en) * 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
PE20090983A1 (es) * 2007-11-09 2009-08-13 Genentech Inc Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina
LT3002298T (lt) 2007-11-21 2019-12-10 Univ Oregon Health & Science Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
WO2009090493A2 (en) * 2007-12-06 2009-07-23 Korea Advanced Institute Of Science And Technology Tlr4 decoy receptor protein
CA2708251C (en) * 2007-12-07 2016-04-12 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
KR101304150B1 (ko) 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
EP2252631B1 (en) 2008-04-02 2016-04-13 MacroGenics, Inc. Bcr-complex-specific antibodies and methods of using same
PL2439212T3 (pl) * 2008-05-02 2017-06-30 Novartis Ag Ulepszone cząsteczki wiążące na bazie fibronektyny oraz ich zastosowanie
BRPI0912003A2 (pt) 2008-05-06 2016-07-12 Genentech Inc afinidade de variantes de crig maturadas
CA2726845C (en) * 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
NZ590358A (en) 2008-07-23 2012-04-27 Hanmi Holdings Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
BRPI0923157B1 (pt) 2008-12-19 2021-12-28 University Of Zürich Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática
US20100159485A1 (en) * 2008-12-19 2010-06-24 Centre For Dna Fingerprinting And Diagnostics Detection of mycobacterium tuberculosis
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
EP2411412B1 (en) 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against light and uses thereof
MX347978B (es) 2009-04-01 2017-05-22 Genentech Inc * Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina.
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
BRPI1013877A2 (pt) 2009-04-10 2017-08-15 Ablynx Nv Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
RU2503688C2 (ru) 2009-04-22 2014-01-10 Алтеоген, Инк Слитый белок или пептид с увеличенным временем полужизни in vivo, поддерживаемый за счет замедленного высвобождения in vivo, и способ увеличения времени полужизни in vivo с его применением
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
WO2010129917A2 (en) 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
CA2983972C (en) 2009-05-15 2023-05-02 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp.alpha.-cd47 interaction
BRPI1009716A2 (pt) 2009-06-15 2016-10-11 Biokine Therapeutics Ltd ligações péptidicas de quemoquina, capazes de inibir o curso da autoimunidade, inflamação e câncer
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
CN107441487B (zh) * 2009-08-28 2021-09-14 泰华制药国际有限公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
LT2486141T (lt) 2009-10-07 2018-05-25 Macrogenics, Inc. Fc regioną turintys polipeptidai, pasižymintys pagerinta efektorine funkcija dėl fukozilinimo laipsnio pasikeitimų, ir jų naudojimo būdai
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
JP5743234B2 (ja) 2010-01-15 2015-07-01 キリン−アムジェン・インコーポレーテッド 抗体製剤及び治療レジメン
EP2536435B1 (en) 2010-02-18 2017-11-15 Janssen Biotech, Inc. Monkey homolog of human interferon omega
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
JP6034283B2 (ja) 2010-03-26 2016-11-30 トラスティーズ・オブ・ダートマス・カレッジ Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US20110250215A1 (en) * 2010-04-02 2011-10-13 Athena Discovery, Inc. Structurally-related relaxin-fusion proteins with extended in vivo half-lives
WO2011130533A1 (en) 2010-04-16 2011-10-20 Centocor Ortho Biotech Inc. Engineered plant cysteine proteases and their uses
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
EP2582387A2 (en) 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
US9441029B2 (en) 2010-08-06 2016-09-13 Genzyme Corporation VEGF antagonist compositions and uses thereof
EP2611832B1 (en) 2010-09-02 2017-11-29 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
CN105017429B (zh) 2010-09-21 2021-04-06 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CN103429616B (zh) 2010-09-27 2016-08-10 詹森生物科技公司 结合人胶原ii的抗体
EP2627672B1 (en) 2010-10-11 2018-08-01 Biogen Idec International Neuroscience GmbH Human anti-tau antibodies
KR101333958B1 (ko) * 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
EP2633317A1 (en) 2010-10-25 2013-09-04 Genentech, Inc. Treatment of gastrointestinal inflammation and psoriasis a
ES2970234T3 (es) 2010-11-08 2024-05-27 Ablynx Nv Polipéptidos que se unen a CXCR2
CA2818781C (en) 2010-12-17 2019-10-08 Neurimmune Holding Ag Human anti-sod1 antibodies
BR112013029932A2 (pt) 2011-05-20 2017-01-31 Alderbio Holdings Llc composições anti-cgrp e usos das mesmas
CN108359008B (zh) 2011-05-20 2022-03-29 H.伦德贝克公司 抗cgrp或抗cgrp-r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
MX356269B (es) 2011-05-20 2018-05-21 Alderbio Holdings Llc Uso de anticuerpos anti-cgrp y fragmentos de anticuerpo para prevenir o inhibir la fotofobia o aversion a la luz en sujetos en necesidad de los mismos, especialmente pacientes con migraña.
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
SG195082A1 (en) 2011-05-25 2013-12-30 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
PT2723379T (pt) 2011-06-23 2018-11-14 Univ Of Zuerich Moléculas de ligação anti-alfa-sinucleína
EP3628327A1 (en) 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
KR20140039257A (ko) * 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신을 방출하는 융합 단백질 및 이의 용도
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2849195A1 (en) * 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
ES2888249T3 (es) * 2011-10-11 2022-01-03 Univ Zuerich Medicamento de combinación que comprende IL-12 y un agente para el bloqueo de moléculas inhibidoras de linfocitos T para terapia tumoral
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
AU2012328880B2 (en) 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
EP2802653A4 (en) 2012-01-10 2015-09-02 Univ Colorado Regents ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF
WO2013130959A1 (en) 2012-03-02 2013-09-06 Vaccinex, Inc. Methods for the treatment of b cell-mediated inflammatory diseases
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US9695454B2 (en) 2012-05-23 2017-07-04 Glykos Finland Oy Production of fucosylated glycoproteins
CA2877533C (en) 2012-06-22 2022-08-16 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CA2878404A1 (en) 2012-07-10 2014-01-16 The Trustees Of The University Of Pennsylvania Biomaterials for enhanced implant-host integration
WO2014022759A1 (en) 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
DK2888283T3 (en) 2012-08-24 2018-11-19 Univ California ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE
CN105246507B (zh) 2012-09-07 2019-01-25 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CN110066341B (zh) 2012-12-17 2023-01-31 Pf阿根图姆知识产权控股有限责任公司 蛋白、缀合物、药物组合物、DNA构建体、宿主细胞及制备人SIRPα融合蛋白的方法
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
WO2014102399A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
AU2013205589A1 (en) 2013-03-08 2014-09-25 Vaccinex, Inc. Anti-CXCL13 antibodies and associated epitope sequences
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9908938B2 (en) 2013-03-14 2018-03-06 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
US10588949B2 (en) 2013-03-15 2020-03-17 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
TR201809571T4 (tr) 2013-03-15 2018-07-23 Hoffmann La Roche Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
DK2981822T3 (da) 2013-05-06 2020-12-07 Scholar Rock Inc Sammensætninger og fremgangsmåder til vækstfaktormodulation
EP3004877A4 (en) 2013-06-06 2017-04-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US20160297875A1 (en) 2013-12-07 2016-10-13 Case Western Reserve University Compositions and methods of treating thrombosis
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CA3190821A1 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3096776B1 (en) * 2014-01-22 2020-12-02 Antagonis Biotherapeutics GmbH Novel glycosaminoglycan-antagonising fusion proteins and methods of using same
KR102274964B1 (ko) 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US20170174772A1 (en) 2014-03-31 2017-06-22 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
EP3154585B1 (en) 2014-06-11 2022-02-23 Kathy A. Green Use of vista agonists and antagonists to suppress or enhance humoral immunity
US9925247B2 (en) 2014-06-30 2018-03-27 Altor Bioscience Corporation IL-15-based molecules and methods of use thereof
AU2015293949B2 (en) 2014-07-21 2019-07-25 Teknologian Tutkimuskeskus Vtt Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
WO2016022597A1 (en) 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10717778B2 (en) 2014-09-29 2020-07-21 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
EP3201228A2 (en) 2014-09-30 2017-08-09 Neurimmune Holding AG Human-derived anti-dipeptide repeats (dprs) antibody
AU2015334984A1 (en) 2014-10-21 2017-04-13 Ablynx Nv Treatment of IL-6R related diseases
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
CN107407677B (zh) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
US11820807B2 (en) 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
GEP20227447B (en) 2015-08-07 2022-12-12 Alx Oncology Inc Constructs having sirp-alpha domain or variant thereof
US10633445B2 (en) 2015-09-15 2020-04-28 Board Of Regents The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
WO2017062757A1 (en) 2015-10-08 2017-04-13 Massachusetts Institute Of Technology In situ expansion of engineered devices for regeneration
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
EP3390378B1 (en) 2015-12-17 2022-03-30 AlonBio Ltd. Small molecules against cancer
ES2818531T3 (es) 2015-12-17 2021-04-13 Biokine Therapeutics Ltd Moléculas pequeñas para inhibir la actividad de las quimiocinas y/o el crecimiento de células cancerosas
WO2017117558A1 (en) 2015-12-31 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
CN114874322A (zh) 2016-03-10 2022-08-09 维埃拉生物股份有限公司 Ilt7结合分子及其使用方法
UA125382C2 (uk) 2016-04-15 2022-03-02 Імьюнекст Інк. Антитіла проти людського vista та їх застосування
SG11201808979UA (en) 2016-04-15 2018-11-29 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2017205726A1 (en) 2016-05-27 2017-11-30 Altor Bioscience Corporation Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
SG10201913032TA (en) 2016-09-23 2020-02-27 Teva Pharmaceuticals Int Gmbh Treating refractory migraine
SG11201903306SA (en) 2016-10-21 2019-05-30 Altor Bioscience Corp Multimeric il-15-based molecules
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3052095A1 (en) 2017-01-30 2018-08-02 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
BR112019017743A2 (pt) 2017-02-28 2020-04-07 Sanofi Sa rna terapêutico
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
WO2018165208A1 (en) 2017-03-06 2018-09-13 Altor Bioscience Corporation Il-15-based fusions to il-12 and il-18
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
EP3618865A4 (en) 2017-05-05 2021-05-05 Vaccinex, Inc. 4D ANTI-SEMAPHORIN HUMAN ANTIBODY
AU2018323455B2 (en) 2017-08-28 2022-02-03 Altor Bioscience Llc IL-15-based fusions to IL-7 and IL-21
TW201940182A (zh) 2018-01-22 2019-10-16 美商安德賽特公司 Car t 細胞之使用方法
MA51676A (fr) 2018-01-26 2021-05-05 Hoffmann La Roche Protéines de fusion il-22 fc et procédés d'utilisation
BR112020015016A2 (pt) 2018-01-26 2020-12-29 Genentech, Inc. Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
KR20200123118A (ko) 2018-02-21 2020-10-28 제넨테크, 인크. IL-22 Fc 융합 단백질로 치료를 위한 투약
WO2019191100A1 (en) 2018-03-26 2019-10-03 Altor Bioscience Llc Anti-pdl1, il-15 and tgf-beta receptor combination molecules
KR102194644B1 (ko) 2018-04-26 2020-12-24 주식회사 굳티셀 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
JP7340862B2 (ja) * 2018-06-28 2023-09-08 国立大学法人 岡山大学 好中球貪食能増強剤
CN112543644A (zh) * 2018-07-24 2021-03-23 古德T细胞有限公司 一种预防和治疗免疫相关疾病的组合物
CN110964116A (zh) 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
CA3123237A1 (en) 2019-01-08 2020-07-16 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-cgrp antibodies
JP2022518208A (ja) 2019-01-15 2022-03-14 ヤンセン バイオテツク，インコーポレーテツド 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
CA3127748A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
AU2020221821A1 (en) 2019-02-13 2021-08-26 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
KR20210141998A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 제조 방법
EP3938390A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2020223121A1 (en) 2019-04-30 2020-11-05 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
IL288144B2 (en) 2019-05-15 2024-03-01 Alonbio Ltd Compounds to treat cancer, to inhibit chemokines and/or to kill cells
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP2022534212A (ja) 2019-05-31 2022-07-28 エーエルエックス オンコロジー インコーポレイテッド 免疫チェックポイント阻害剤と組み合わせてｓｉｒｐアルファｆｃ融合によりがんを治療する方法
WO2020245677A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
JP2022536279A (ja) 2019-06-03 2022-08-15 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
TW202142562A (zh) 2020-03-05 2021-11-16 美商迪亞醫藥美國公司 烏司他丁多肽
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
JPWO2021230233A1 (es) * 2020-05-14 2021-11-18
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2023173084A1 (en) 2022-03-11 2023-09-14 University Of Rochester Cyclopeptibodies and uses thereof
KR20230156844A (ko) 2022-05-02 2023-11-14 노보 노르디스크 에이/에스 고농도 조성물 및 피하 투여에 적합한 신규한 항-angptl3 항체

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
DE2247163A1 (de) 1972-09-26 1974-03-28 Merck Patent Gmbh Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS5811808A (ja) 1981-07-16 1983-01-22 Niles Parts Co Ltd 方位検出表示回路
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
JPS59125144A (ja) 1982-12-30 1984-07-19 ソニー株式会社 デイジタル信号伝送方法
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0126023B1 (fr) 1983-04-20 1990-09-05 Youri Agabekov Rampe d'alimentation électrique
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
DE3523701A1 (de) * 1985-07-03 1987-01-08 Bayer Ag Verfahren zur herstellung von proteinen und polypeptiden
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
EP0256654B1 (en) 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
NO873164L (no) 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
GB8623843D0 (en) 1986-10-03 1987-10-21 Airtech Ltd Detection of unsafe voltages on mobile equipment
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
CA1339445C (en) * 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
ATE122238T1 (de) * 1987-06-10 1995-05-15 Dana Farber Cancer Inst Inc Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
JP2755395B2 (ja) * 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
ZA89430B (en) * 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
ATE140963T1 (de) * 1988-01-22 1996-08-15 Zymogenetics Inc Verfahren zur herstellung von sekretierten rezeptoranalogen
GB8801756D0 (en) 1988-01-27 1988-02-24 Shell Int Research Copolymer composition
SE8802176D0 (sv) * 1988-06-10 1988-06-10 Kabigen Ab Fusion protein and its use
WO1990002338A1 (en) * 1988-08-19 1990-03-08 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
DE68913658T3 (de) * 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
EP1201756A3 (en) 1988-12-22 2002-10-30 Genentech, Inc. Method for preparing water soluble polypeptides
CA2010321C (en) * 1989-02-21 2004-04-06 Thomas F. Tedder Lymphocyte-associated cell surface protein
DK0391088T3 (da) * 1989-03-16 1997-06-16 Blood Res Center Anvendelse af funktionelle derivater af det intercellulære adhæsionsmolekyle ICAM-1 til antiviral terapi
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ATE92107T1 (de) * 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
DE69029036T2 (de) * 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991002743A1 (en) * 1989-08-23 1991-03-07 The General Hospital Corporation Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
ATE228566T1 (de) * 1989-09-20 2002-12-15 Abbott Lab Verfahren zur herstellung von fusionsproteinen

Also Published As

Publication number Publication date
EP0526452A1 (en) 1993-02-10
EP1029870A2 (en) 2000-08-23
EP1970386A8 (en) 2009-07-08
DE122008000063I2 (de) 2011-06-16
EP0526452B1 (en) 2001-02-21
JPH05503009A (ja) 1993-05-27
DK0526452T4 (da) 2007-05-07
DE69033705T2 (de) 2001-08-02
DE122008000063I1 (de) 2009-02-19
EP1029870A3 (en) 2000-12-13
DK1029870T3 (da) 2008-09-29
CA2072642A1 (en) 1991-05-23
WO1991008298A3 (en) 1991-10-17
HK1013298A1 (en) 1999-08-20
GR3035856T3 (en) 2001-08-31
ATE396735T1 (de) 2008-06-15
CA2072642C (en) 2002-07-23
DE69033705T3 (de) 2007-07-12
ES2155819T5 (es) 2007-09-16
NL300372I1 (nl) 2009-02-02
ES2308826T3 (es) 2008-12-01
EP1970386A2 (en) 2008-09-17
DE69034253D1 (de) 2008-07-10
DK0526452T3 (da) 2001-06-18
US5116964A (en) 1992-05-26
EP1029870B1 (en) 2008-05-28
WO1991008298A2 (en) 1991-06-13
LU91498I2 (fr) 2009-01-19
HK1030222A1 (en) 2001-04-27
EP0526452B2 (en) 2007-01-03
DE69033705D1 (de) 2001-03-29
JP2002325589A (ja) 2002-11-12
ATE199261T1 (de) 2001-03-15

Similar Documents

Publication Publication Date Title
ES2155819T3 (es) Inmunoglobulinas hibridas.
DK564989A (da) Bindingsproteiner
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
DE3382837T2 (de) Herstellung von funktionellen, menschlichen Urokinaseproteinen
BR8107293A (pt) Polipetidio anti-viral dna de duplo cordao veiculo de expressao plasmidico replicavel microorganismo transformado plasmidio processo de formacao do dito dna e do dito polipeptidio composicao farmaceutica e uso do dito polipeptidio
DE69503038D1 (de) Zellzyklusprotein in Säugetieren
DE69535719D1 (de) Fas-antigenbindender ligand
ES545725A0 (es) Procedimiento para preparar peptidos de interferon
ATE102994T1 (de) Verfahren zur herstellung von proteinen.
NO169819C (no) Fremgangsmaate for fremstilling av hybrid polypeptid og dna-molekyl for bruk i denne
KR900011856A (ko) 혼성 아미노 수지 조성물
DE3767659D1 (de) Verfahren und testelement zum auffinden von zellaesionen.
KR900011857A (ko) 혼성 아미노 수지 조성물
ATE94905T1 (de) Verfahren zur herstellung von fremdproteinen in streptomyceten.
KR900011855A (ko) 혼성 아미노 수지 조성물
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
ATE91303T1 (de) Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen.
ATE17014T1 (de) Verfahren zur herstellung von polymerisaten mit seitenstaendig gebundenen polyalkylenoxidketten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 526452

Country of ref document: ES